Description: Medigene is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases.
Home Page: www.medigene.com
Lochhamer Strasse 11
Munich,
82152
Germany
Phone:
49 89 2000 330
Officers
| Name | Title |
|---|---|
| Dr. Dolores J. Schendel | Chief Scientific Officer, Member of Exec. Management Board and Head of R&D |
| Dr. Selwyn Ho MB BS, MBBS | CEO & Member of Exec. Management Board |
| Dr. Ernst-Ludwig Winnacker | Co-Founder & Chairman Scientific Advisory Board |
| Dr. Birger Kohlert | Chief Financial Officer |
| Dr. Rene Goedkoop | Acting Chief Medical Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 5.2439 |
| Price-to-Book MRQ: | 0.9245 |
| Price-to-Sales TTM: | 1.865 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 61 |